| Literature DB >> 26474040 |
Myra Noemi Chávez1, Thilo Ludwig Schenck2, Ursula Hopfner3, Carolina Centeno-Cerdas4, Ian Somlai-Schweiger5, Christian Schwarz6, Hans-Günther Machens3, Mathias Heikenwalder7, María Rosa Bono8, Miguel L Allende9, Jörg Nickelsen6, José Tomás Egaña10.
Abstract
The use of artificial tissues in regenerative medicine is limited due to hypoxia. As a strategy to overcome this drawback, we have shown that photosynthetic biomaterials can produce and provide oxygen independently of blood perfusion by generating chimeric animal-plant tissues during dermal regeneration. In this work, we demonstrate the safety and efficacy of photosynthetic biomaterials in vivo after engraftment in a fully immunocompetent mouse skin defect model. Further, we show that it is also possible to genetically engineer such photosynthetic scaffolds to deliver other key molecules in addition to oxygen. As a proof-of-concept, biomaterials were loaded with gene modified microalgae expressing the angiogenic recombinant protein VEGF. Survival of the algae, growth factor delivery and regenerative potential were evaluated in vitro and in vivo. This work proposes the use of photosynthetic gene therapy in regenerative medicine and provides scientific evidence for the use of engineered microalgae as an alternative to deliver recombinant molecules for gene therapy.Entities:
Keywords: Algae biotechnology; Biomaterials; Drug delivery; Hypoxia; Molecular therapy; Oxygen; Regenerative medicine
Mesh:
Substances:
Year: 2015 PMID: 26474040 DOI: 10.1016/j.biomaterials.2015.10.014
Source DB: PubMed Journal: Biomaterials ISSN: 0142-9612 Impact factor: 12.479